

New Hampshire Medicaid Fee-for-Service Program

Pulmonary Arterial Hypertension Criteria

Phosphodiesterase Type 5 (PDE-5) Inhibitors Only

Approval Date: January 14, 2022

Medications

Brand Names	Generic Names	Dosage
Adcirca®	tadalafil	20 mg
Revatio®	sildenafil	20 mg tablet, injection: 10 mg/12.5 mL in a single use vial; oral suspension: 10 mg/mL

Criteria for Approval

1. Patient is ≥ 18 years old; **AND**
2. Diagnosis of pulmonary arterial hypertension (PAH); **AND**
3. Prescribed by or in consultation with a cardiologist or pulmonologist experienced in the diagnosis and treatment of PAH; **AND**
4. For oral suspension **ONLY**, is unable to take oral tablets.

Criteria for Denial

1. Diagnosis of erectile dysfunction without a diagnosis of PAH
2. Concomitant use of organic nitrates
3. Concomitant use of guanylate cyclase (GC) Stimulators or other PAH medications
4. Sildenafil only: Concomitant use with human immunodeficiency virus (HIV) protease inhibitors or elvitegravir/cobicistat/tenofovir/emtricitabine

References

Available upon request.

Revision History

Reviewed by	Reason for Review	Date Approved
DUR Board	New	03/20/2017
Commissioner	Approval	06/08/2017
DUR Board	Review	03/12/2019
Commissioner Designee	Approval	04/05/2019
DUR Board	Review	06/30/2020
Commissioner Designee	Approval	08/07/2020
DUR Board	Review	12/02/2021
Commissioner Designee	Approval	01/14/2022